Objective: To elucidate the direct effects of gonadotropin-releasing hormone agonist (GnRHa) on the growth of human uterine leiomyoma cells, cell proliferation and apoptosis in cultured leiomyoma cells treated with GnRHa were investigated. Methods: Isolated leiomyoma cells were subcultured in DMEM supplemented with 10% FBS for 5 days and stepped down to serum-free conditions for an additional 6 days in the presence or absence of graded concentrations of GnRHa (10 29 mol/l to 10 212 mol/l). The effects of GnRHa on the number of viable cells, expression of proliferating cell nuclear antigen (PCNA), Fas and Fas ligand, and apoptosis in cultured leiomyoma cells were examined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide) assay, immunocytochemical analysis, Western blot analysis and TUNEL assay respectively. RT-PCR was performed to detect the expression of GnRH receptor mRNA in cultured leiomyoma cells. Results: Treatment with GnRHa resulted in a decrease in the number of cultured viable leiomyoma cells assessed by MTT assay in a dose-dependent manner compared with that in control cultures ðP , 0:01Þ: The growth inhibition of cultured leiomyoma cells treated with GnRHa in concentrations higher than 10 210 mol/l was associated with the suppression of the proliferative potential characterized by a decrease in PCNA-positive rate of the cultured cells ðP , 0:01Þ and an increase in the apoptosis-positive rate assessed by TUNEL assay ðP , 0:05 and P , 0:01Þ: GnRHa markedly increased the expression of Fas and induced the expression of Fas ligand in the cultured leiomyoma cells on the basis of Western blot analysis. These direct effects of GnRHa on the number of viable cultured leiomyoma cells, PCNA-positive rate, apoptosis-positive rate and Fas/Fas ligand expression in the cultured leiomyoma cells were only attained after the 4-day treatment. RT-PCR analysis revealed that GnRH receptor mRNA was expressed in cultured leiomyoma cells.
Introduction
Gonadotropin-releasing hormone (GnRH) stimulates the synthesis and release of pituitary gonadotropin luteinizing hormone (LH) and follicle-stimulating hormone (FSH) via a high-affinity membrane receptor (GnRH receptor) which, in turn, promotes the development of gonadal function (1) . Continuous administration of GnRH agonists (GnRHa), by downregulating the number and sensitivity of GnRH receptors, suppresses pituitary gonadotropin biosynthesis and release, which leads to a decrease in estrogen and progesterone secretion from the ovary (2, 3) . In this context, the chronic administration of GnRHa has been used in therapy for sex steroid hormonedependent tumors, including uterine leiomyoma, breast cancer, prostate cancer, endometrial cancer and ovarian cancer (4 -8) . The effects of continuous administration of GnRHa on uterine leiomyoma in vivo are known to be characterized by the reduction in the size of the tumor (9) .
In recent years, there has been a growing body of evidence to indicate that a variety of normal and malignant tissues and cell lines express GnRH and GnRH receptors and contain GnRH-binding sites, which suggests a direct GnRH action on peripheral tissues. These GnRH-binding sites are present in endometrium, endometrial carcinoma, ovary, and placenta as well as in breast, ovarian, endometrial, prostatic, and hepatoma cancer cell lines (10 -18) . In vitro studies with breast, prostatic and ovarian cancer cell lines suggest that GnRHa directly inhibits cell proliferation and induces apoptosis (7, 19, 20) . RT-PCR analysis revealed that uterine leiomyoma, unaffected myometrium, and isolated myometrial smooth muscle cells maintained in primary culture express GnRH and GnRH receptor mRNA (21, 22) . Whether the growth of leiomyoma cells is directly inhibited by GnRHa, however, is far from clear. Thus, the direct effects of GnRHa (buserelin) on the growth of cultured human leiomyoma cells have been evaluated.
Materials and methods

Peptides and antibodies
Monoclonal antibody to human proliferating cell nuclear antigen (PCNA; Ab-1, PC10) was purchased from Oncogene Science, Inc (Cambridge, MA, USA). Polyclonal antibodies to human Fas and Fas ligand were from Transduction Laboratories (Lexington, KY, USA). Buserelin and leuprolide were obtained from Aventis Pharma Ltd (Tokyo, Japan) and Takeda Pharmaceutical Co. (Osaka, Japan) respectively.
Tissue collection, cell isolation and monolayer culture
Uterine leiomyoma tissues were collected from premenopausal women undergoing hysterectomy for leiomyoma who were not receiving any hormonal treatment at the time of surgery. The tissues were collected at Kobe University Hospital after the institutional review board approved the study protocol for the collection. Informed consent was obtained from each patient before surgery for the use of uterine tissues in the present study. Uterine leiomyoma tissues were dissected from endometrial cell layers, washed in phosphatebuffered saline (PBS), cut into small pieces, and digested in 0.2% collagenase (wt/vol.) at 37 8C for 3 -5 h (23). The leiomyoma cells were collected by centrifugation at 460 £ g for 5 min and washed several times with PBS containing 1% antibiotic solution.
Isolated leiomyoma cells were cultured at 37 8C in a humidified atmosphere of 5% CO 2 -95% air in phenol red-free DMEM (24) supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin and 1.25 U/ml nystatin. For the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide) assay, isolated cells were subcultured in 96-well flat-bottom cell culture plates at an approximate density of 2:5 £ 10 3 cells/ well in the presence of 10% FBS for 48 h. The cells were made quiescent by incubation under serum-free conditions for 48 h, and then treated with graded concentrations of buserelin (10 212 mol/l, 10 211 mol/l, 10 210 mol/l and 10 29 mol/l) for 2, 4, and 6 days. For immunostaining and apoptosis analysis, the isolated leiomyoma cells were plated in 2-well chamber slides at an approximate density of 5 £ 10 4 cells/ml in 1 ml DMEM containing 10% FBS. After 5 days subculture, the cells were stepped down to serum-free conditions for 2, 4, and 6 days, in the presence or absence of graded doses of buserelin (10 210 mol/l and 10 29 mol/l). For Western blot analysis, 5 £ 10 5 cells/dish were plated in plastic plates (10 cm in diameter), subcultured in the presence of 10% FBS for 5 days, and then treated with graded doses of buserelin for 2, 4, and 6 days and submitted to protein extraction.
Characterization of the cultured cells was performed using immunostaining with monoclonal antibodies to a muscle-specific protein, desmin, to a class of intermediate filament protein present in fibroblasts, vimentin, and to a cytoskeletal protein for epithelial cells, cytokeratin (19) .
These cell culture experiments were successfully performed using six different leiomyoma tissue specimens collected from different patients, of which three were from the proliferative phase and the other three were from the secretory phase of the menstrual cycle.
Cell count by MTT colorimetric assay
The number of cultured viable cells was determined after 2, 4, and 6 days of treatment with buserelin using cell proliferation MTT assay. First, MTT (Chemicon, Harrow, UK) was dissolved in PBS (pH 7.4) at 5 mg/ml, filter sterilized, and stored at 4 8C in a darkened bottle. At the end of the treatment, 0.01 ml MTT (5 mg/ml) was added to each well and the plates were incubated at 37 8C for 4 h. Then, 0.1 ml isopropanol was added to each well and mixed thoroughly by repeated pipetting with a multichannel pipettor. Within 1 h, the absorbance was measured on an ELISA plate reader with a test wavelength of 570 nm and a reference wavelength of 630 nm. Because the MTT method is based on the activity of mitochondrial dehydrogenases, the enzymatic activity may be affected by various experimental conditions. To exclude this possibility, we estimated the cell number by direct counting and set up a standard curve with each experiment. The results showed a high correlation (r 2 ¼ 0:90 to 0.95) with those obtained by the MTT method. Cell number was estimated by extrapolating the optical density readings from the standard curve.
Immunocytochemical staining
After removal of the culture medium, the cultured cells were washed with PBS twice and fixed with 4% buffered neutral formaldehyde solution. Then, immunocytochemical staining was performed by the avidin/biotin immunoperoxidase method with the use of a polyvalent immunoperoxidase kit (Omnitags, Lipshow, MI, USA) as previously described by Maruo and Mochizuki (25) . A mouse monoclonal antibody to human PCNA was used as the primary antibody in this study. To ensure the specificity of the immunological reaction, the cultured cells were subjected to the same immunoperoxidase method, except that the primary antibody was replaced by non-immune murine IgG (Miles, Erkhardt, IN, USA) at the same dilution as the specific antibody. The replacement of the specific primary antibody with non-immune murine IgG resulted in a lack of positive immunostaining. Immunostaining was analyzed by two investigators in a blinded fashion without knowledge of the experimental group. All stained nuclei were scored as positive for PCNA. The PCNA-positive rate was determined by observing more than 2000 nuclei for each of the experimental samples.
Terminal deoxynucleotide transferasemediated deoxy-UTP nick end labeling (TUNEL assay)
ApopTag In Situ Apoptosis Detection Kits (Intergen Co., Purchase, NY, USA) were used to identify apoptosis in cultured cells. In brief, after removal of the culture medium, the cells were washed with PBS twice and fixed. Then, 3
0 -hydroxyl-DNA strand breaks in cultured cells were enzymatically labeled with digoxigenin-nucleotide by terminal deoxynucleotidyl transferase and subsequently exposed to horseradish peroxidase-conjugated antidigoxigenin antibody. Staining was developed in diaminobenzidine and slides were counterstained with hematoxylin. Apoptosis of cultured cells was analyzed by two investigators in a blinded fashion without knowledge of the experimental group. All stained nuclei scored as positive for apoptosis. The apoptosis-positive rate was determined by observing more than 2000 nuclei for each of the experimental samples.
Western blot analysis
At the termination of cultures, cultured cells were washed twice with PBS and harvested on ice by scraping the dishes with a disposable cell scraper in the presence of lysis buffer consisting of 50 mmol/l Tris -HCl (pH 8.0), 150 mmol/l NaCl, 0.1% sodium dodecylsulfate (SDS), 100 mg/ml phenylmethylsulfonyl fluoride (PMSF), 1 mg/ml aprotinin, 1% NP-40 and 0.5% deoxycholic acid (sodium salt). The harvested cells were incubated at 4 8C for 20 min and centrifuged for 30 min at 10 000 £ g and the supernatant was collected. Protein estimation of the supernatants was performed by the Bradford assay. Each 60 mg aliquot of the protein extracts was electrophoresed on a 10% SDS-polyacrylamide gel (SDS-PAGE) and transferred to a polyvinylidene difluoride (PVDF) membrane. The membrane was blocked with 5% nonfat dry milk in Trizma base saline buffer (TBS) at 4 8C overnight, then incubated at room temperature for 1.5 h with corresponding antibodies which were diluted 1:1000 with TBS. The antigen-antibody complexes were detected with the secondary antibody using the ECL chemiluminescence detection system (Amersham, Arlington Heights, IL, USA).
These experiments were performed with six different cultured cell specimens with similar results, and the reported results are representative. Three experiments were performed with the cells obtained in the proliferative phase, and the other three were performed with the cells obtained in the secretory phase of the menstrual cycle.
RT-PCR for GnRH receptor
Total RNA was isolated from cultured leiomyoma cells without any hormonal treatment using Rneasy Mini Kit (Qiagen, Inc., Chatsworth, CA, USA). First strand complementary DNA (cDNA) was synthesized from 2 mg total RNA using an Omniscript RT kit (Qiagen, Inc.). PCR was performed using 1 ml cDNA as template, 6.25 pmol/l of each primer, 2.5 mmol/l dNTPs, 0.125 UTaq DNA polymerase (Roche-Diagnostics Inc., Mannheim, Germany), 1 £ reaction buffer containing 10 mmol/l Tris -HCl, pH 8.3, 50 mmol/l KCl, 1.5 mmol/l MgCl 2 and 0.01% gelatin in 25 ml reaction volume. The amplification procedure, performed on a Gene Amp PCR System 9600-R (Perkin Elmer Corp., Norwalk, CT, USA), was as follows: intial denaturation step at 94 8C for 5 min, denaturation step at 94 8C for 30 s, annealing step at 55 8C for 30 s, and extension step at 72 8C for 30 s respectively. The reactions were subjected to 34 cycles, using human-specific PCR primers for GnRH receptor (sense 5 0 -TCTAGCAGACAGCT-CTGGACA-3 0 ; anti-sense 5 0 -GAGTCTTCAGCCGTGC-TCTT-3 0 ) (26) . In addition, tubes containing all PCR components except the RT reaction mixture were also amplified, which served as a negative control to check for the presence of DNA that may have been carried over from a previous reaction. RT-PCR of RNA extracted from human pituitary was used as the positive control. PCR for b-actin was performed on all samples to test for the possibility of RNA degradation or RNA transcription default. The PCR products were cloned and the sequence analysis revealed their specificity.
Statistical analysis
Statistical evaluation was performed by analysis of variance, followed by the Student -Newman -Keuls test. A value of P , 0:05 was considered to be statistically significant.
Results
210 mol/l or 10 29 mol/l GnRHa resulted in a significant inhibition of the growth of cultured cells after 4 days of treatment, although no significant effect was attained after 2 days of treatment. This inhibition was dose-dependent, with the maximal effect occurring at the highest dose (10 29 mol/l) tested, and persisted after the 6-day treatment (Fig. 1) . PCNA-positive nuclei were still abundant after 2 days of treatment with either 10 210 mol/l or 10 29 mol/l GnRHa (Fig. 2B) without apparent change compared with those in control cultures ( Fig. 2A) . However, either the 4-day treatment or 6-day treatment with 10 210 mol/l GnRHa resulted in an apparent decrease in PCNA-positive nuclei compared with those in control cultures ( Fig. 2C and E) and the apparent decrease in PCNA-positive nuclei was more remarkable with treatment with 10 29 mol/l GnRHa ( Fig. 2D and F) . 
Effects on Fas and Fas ligand expression and apoptosis
Compared with control cultures for 4 days and 6 days ( Fig. 4A and C) , apoptotic cells were more abundantly apparent after treatment with 10 29 mol/l GnRHa for either 4 days (Fig. 4B ) or 6 days (Fig.  4D ). Figure 5 indicates the apoptosis-positive rate which was determined by observing more than 2000 nuclei for each dose and time point experiment by microscopy. No significant effect of GnRHa was attained after the 2-day treatment period. However, treatment with 10 29 mol/l GnRHa produced a significant increase in the apoptosis-positive rate of cultured leiomyoma cells after both the 4-day treatment ðP , 0:05Þ or the 6-day treatment ðP , 0:01Þ; whereas treatment with 10 210 mol/l GnRHa showed a significant increase in the apoptosis-positive rate only after 6 days of treatment ðP , 0:01Þ:
Western blot analysis of proteins extracted from leiomyoma cells cultured respectively for 2, 4 and 6 days under serum-free conditions in the presence or absence of graded doses of GnRHa revealed that in cultured leiomyoma cells in control cultures for 2, 4 and 6 days, Fas ligand expression was negligible and Fas expression was minimal. However, after 4 days of treatment with either 10 210 mol/l or 10 29 mol/l GnRHa, the expression of Fas ligand with a molecular weight of 37 kDa became apparent and the Fas ligand expression became more abundant in cultured leiomyoma cells treated with either 10 210 mol/l or 10 29 mol/l GnRHa for 6 days (Fig.  6 ). The expression of Fas with a molecular weight of 45 kDa had no apparent change after 2 days of treatment with either 10 210 mol/l or 10 29 mol/l GnRHa, but was markedly increased in the cultured leiomyoma cells after 4 days and 6 days of treatment compared with that in control cultures (Fig. 7) . Similar results were obtained with the other GnRH agonist, leuprolide (data not shown).
The expression of GnRH receptor mRNA in leiomyoma cells
The expression of GnRH receptor mRNA in cultured leiomyoma cells without any hormonal treatment was examined using RT-PCR. With the use of GnRH receptor PCR primers, an expected 251 bp PCR product was detected in cultured leiomyoma cells which were isolated from leiomyomas either in the proliferative phase or in the secretory phase of the menstrual cycle (Fig. 8) .
Discussion
To date, we have known that GnRHa has two different functions: a central action and a peripheral action. Via its central action, chronic administration of GnRHa suppresses pituitary gonadotropin biosynthesis by decreasing the number and sensitivity of GnRH receptors, which leads to the lowering of plasma estradiol (2, 3) . The actions of GnRHa in peripheral tissues, however, are not well defined. GnRHa exerts its action by being recognized by its receptor. The prerequisite for direct action of GnRHa in peripheral tissues is the presence of GnRH receptors in target cells. It is evident that there are GnRH receptors and GnRH-binding sites in many kinds of extrapituitary tissues including leiomyoma (1, 12, 21, 22) . Our data indicating that GnRH receptor mRNA is expressed in cultured leiomyoma cells support the above notion, which indicates a direct GnRHa action in leiomyoma cells. The direct effects of GnRHa on antiproliferation and induction of apoptosis in KOC-2s ovarian cancer cell lines have been reported (7) . In the present study, we have demonstrated for the first time that GnRHa directly inhibited cell proliferation and induced apoptosis in human uterine leiomyoma cells cultured in vitro. On the other hand, Kleinman et al. reported that GnRHa (buserelin) did not affect cell growth in some kinds of human endometrial cancer cell lines (27) . Ho et al. noted that GnRHa exerted biphasic growth effects on IGROV-1 ovarian cancer cells: cell proliferation was enhanced during the first 24 h of exposure to GnRHa, but longer exposure to GnRHa resulted in growth inhibition, which was similar to the central action of GnRHa (28) . This observation supports the dictum that prolonged exposure to GnRH or GnRH analogue resulted in the internalization and down-regulation of GnRH receptors with subsequent desensitization to GnRH stimulation (28) . The different effects of GnRHa on different kinds of cells may be due to two reasons. First, GnRH receptor is coupled to pertussis toxin-sensitive guanosine triphosphate (GTP)-binding proteins of the Gi family in reproductive tract tumors (29, 30) . Recent studies have identified that members of the pertussis toxin-insensitive GTP-binding proteins of the Gq/G11 subfamily mediate the message from GnRH receptor in pituitary gonadotrophs (31, 32) . The difference of GTP-binding protein coupled to GnRH receptor may suggest that the cellular responses to GnRH in the peripheral tumor are distinct from those in the anterior pituitary. Similarly, we speculate that GnRH receptor is coupled to a different subfamily of GTP-binding proteins in different kinds of cells, so that the effects of GnRHa are inconsistent. Secondly, some studies have suggested that GnRHa regulates its own receptor mRNA in extrapituitary tissues and this regulation is tissue specific: in ovarian cancer, high concentrations of the GnRHa (10 27 mol/l and 10 29 mol/l) decreased GnRH receptor mRNA levels, whereas a low concentration (10 211 mol/l) resulted in an up-regulation of GnRH receptor mRNA, but no such down-regulation of GnRH receptor mRNA was observed in placental cells (33) . The tissue-specific regulation of GnRH receptor after GnRHa treatment may lead to the different function of GnRHa.
In the present study, GnRHa inhibited the growth of cultured leiomyoma cells by reducing the number of viable cells from the 4th day of treatment with either 10 210 mol/l or 10 29 mol/l. The decrease in PCNA expression and increase in the apoptosis-positive rate observed with the same dose treatment demonstrate that this growth inhibition of cultured leiomyoma cells by GnRHa is due to the two effects of GnRHa on cultured leiomyoma cells: antiproliferation and induction of apoptosis. After treatment with 10 210 mol/l GnRHa, the lag time required between exerting an antiproliferation effect and induction of apoptosis was 2 days. This indicates that GnRHa may have a rapid effect on the proliferative potential and a delayed effect on apoptosis in cultured leiomyoma cells. The effects of GnRHa treatment on the 210 mol/l or 10 29 mol/l GnRHa decreased the PCNA-positive rate either at the 4-day or 6-day time point, but had no effect at the 2-day time point. **P , 0:01: growth of leiomyoma cells observed in the present study were dose-dependent and a biphasic effect was not noted. From these results, we may propose two hypotheses. One is that prolonged exposure to GnRHa does not result in the internalization of GnRH receptor and desensitization to GnRHa stimulation in leiomyoma cells, unlike in pituitary cells. The other is that GnRHa may up-regulate the expression of GnRH receptor in leiomyoma cells in a dose-dependent manner.
Fas and Fas ligand are transmember proteins of the tumor necrosis factor family of receptors and ligands. Engagement of Fas by Fas ligand triggers a cascade of subcellular events that result in programmed cell death (apoptosis). Fas has been detected in a variety of normal and neoplastic cells, whereas Fas ligand 210 mol/l GnRHa increased the apoptosis-positive rate of cultured leiomyoma cells only after the 6-day treatment, whereas treatment with 10 29 mol/l GnRHa produced a significant increase in the apoptosis-positive rate even after the 4-day treatment. *P , 0:05; **P , 0:01: was initially thought to be expressed only in activated T cells. Recently, it has been reported that Fas ligand is also expressed in some kinds of tumors, such as resected human colorectal cancers, melanomas, hepatocellular cancers, astrocytomas and lung cancers (34) and that GnRHa induces Fas ligand expression in GnRH receptor-bearing tumors (35) . In the present study, we found GnRHa induced apoptosis in the cultured leiomyoma cells, associated with increased expression of Fas and induction of Fas ligand, suggesting that the Fas -Fas ligand system may participate in GnRHa-induced apoptosis in leiomyoma cells in vitro. Interestingly, the expression of Fas increased after the 4-day treatment with 10 210 mol/l GnRHa, whereas the apoptosis-positive rate was not increased at that dose and treatment period. Bennett et al. reported that p53 activation transiently increased surface Fas expression by transport from the Golgi complex, and then induced apoptosis in human vascular smooth muscle cells (36) . It is likely that GnRHa not only increases the expression of Fas but also has a similar effect on p53, which may transport Fas from the Golgi complex to the membrane surface, then plays a role in the induction of apoptosis by combining Fas with Fas ligand. It must be noted that these effects of GnRHa could occur only with the high concentration (10 29 mol/l) and after a long exposure (for 6 days). In our study, what we measured was total Fas of the cell, including surface Fas and intracellular Fas. Since Fas expression was increased after the 4-day treatment with 10 210 mol/l GnRHa, it is likely that the increased expression of Fas might be due to more intracellular Fas and little surface Fas, so that apoptosis could not be induced until the 6-day treatment.
In conclusion, GnRHa directly inhibits the growth of human uterine leiomyoma cells and this growth inhibition is due to two effects: antiproliferation and induction of apoptosis. The Fas -Fas ligand system plays a crucial role in GnRHa-induced apoptosis in cultured leiomyoma cells.
